The Psoriatic Disease Assessment Index (PSODAI) Score to Evaluate Systemic Involvement of Psoriasis [0.03%]
银屑病全身损害评估指数(PSODAI评分)
Yanhua Liang,Baoqing Deng,Epipode Ntawuyamara et al.
Yanhua Liang et al.
Background: To the best of our knowledge, no validated scoring instrument currently exists that comprehensively evaluates both cutaneous manifestations and systemic comorbidities of psoriasis. This multicenter study aimed...
Persistence and Long-Term Disease Control of Interleukin-17 Inhibitors and Interleukin-23 Inhibitors in Patients with Psoriasis: A Nationwide Cohort Study in Japan [0.03%]
日本特应性队列研究中的白细胞介素-17抑制剂和白细胞介素-23抑制剂在银屑病患者中的持久性和长期疾病控制能力
Youran Xu,Tong Li,Chia-Ling Chang et al.
Youran Xu et al.
Introduction: Interleukin-17 inhibitors (IL-17i) and interleukin-23 inhibitors (IL-23i) are advanced therapeutic options for moderate-to-severe psoriasis. In real-world settings, biologic persistence is commonly used as a...
Bidirectional Associations Between Substance Abuse and Psoriasis: A Prospective Cohort Study [0.03%]
双向关联：物质滥用与银屑病的前瞻性队列研究
Xuanlin Che,Jiatong Zhou,Anqi Wang et al.
Xuanlin Che et al.
Background: Psoriasis and substance abuse remains a serious healthcare burden. However, associations between substance abuse and psoriasis have not been elucidated. ...
Zeno Fratton,Stefano Bighetti,Luca Bettolini et al.
Zeno Fratton et al.
Introduction: Psoriasis is a chronic inflammatory disease whose burden peaks in older age groups. Despite the increasing prevalence of elderly patients with moderate-to-severe psoriasis, real-world data on biologics in th...
Global Trends and Future Predictions of Psoriasis Burden: Insights from the GBD 2021 Study [0.03%]
全球银屑病负担的趋势和未来预测：来自GBD 2021研究的见解
Xiaoyu Gu,Xinquan Wang,Yang Bin et al.
Xiaoyu Gu et al.
Background: Psoriasis is a common chronic inflammatory skin disorder, and the global burden of psoriasis has not been fully disclosed. Methods: ...
Antibodies Targeting Gasdermin E as a Potential Therapeutic Option for Psoriasis - A Pilot Study on a Mouse Model [0.03%]
针对Gasdermin E的抗体可能成为银屑病的潜在治疗选择——小鼠模型初步研究
Julia Nowowiejska-Purpurowicz,Justyna M Hermanowicz,Dariusz Pawlak et al.
Julia Nowowiejska-Purpurowicz et al.
Background: Psoriasis is a frequent and complex dermatosis of uncertain origin. A few years ago, a family of gasdermin proteins was implicated in psoriasis pathogenesis. Although the number of therapeutic options for psor...
PEGylated Peptide for Targeted Inhibition of Human Antigen R as a Novel Therapeutic Strategy for Psoriasis: A Proof-of-Concept Study [0.03%]
针对银屑病的新型治疗方法：人抗原R靶向抑制PEG化肽的概念验证研究
Yu-Fon Chen,Yi-Sheng Jiang,Yi-Cheng Chen et al.
Yu-Fon Chen et al.
Introduction: Psoriasis, characterized by dermatological manifestations, exhibits a systemic impact through its association with serious comorbidities, including inflammatory arthritis, cardiovascular and metabolic diseas...
Neurofunctional Reversibility in Psoriasis Vulgaris After IL-17A Inhibition: A Resting-State fMRI and Neurocognitive Analysis [0.03%]
抗IL-17A治疗后寻常型银屑病神经功能可逆性静息态功能磁共振及神经认知分析
Jiayun Liu,Huiping Fan,Rui Sun et al.
Jiayun Liu et al.
Purpose: Interleukin-17A (IL-17A) drives psoriasis and central nervous system neuroinflammation, but clinical research on whether IL-17A-targeted biotherapy modulates brain activity to improve neuropsychiatric outcomes in...
Predictors of Successful Secukinumab Dose Tapering in Moderate-to-Severe Psoriasis: A Retrospective Study [0.03%]
中重度银屑病患者Secukinumab减量成功预测因素的回顾性研究
Jiawen Chen,Zhixun Xiao,Xueting Zeng et al.
Jiawen Chen et al.
Background: Psoriasis (PsO) is a prevalent chronic disease affecting millions, with biologic therapies like secukinumab showing efficacy. With the extensive and prolonged use of secukinumab, identifying strategies for suc...
Evaluating the Role of Disease Duration in Systemic Therapy Response Among Patients with Moderate-to-Severe Psoriasis [0.03%]
中至重度银屑病患者系统治疗反应与病程关系的评估
Min Dai,Yuxiong Jiang,Yujing Xi et al.
Min Dai et al.
Background: Psoriasis is a chronic immune-mediated inflammatory disease. Systemic therapy is usually applicable to patients who have failed topical treatment or phototherapy, but the value of early systemic therapy remain...